All companies
Visit website
EXTENDED LONGEVITY, INC.
OperatingExtended Longevity, Inc.
Healthcare · Fitness · Founded 2019
Extended longevity - Phytotherapeutic formulation protocol
Post-money valuation ⓘ
$45.1M
As of Dec 2022 · from EXTENDED LONGEVITY, INC. Preferred Stock 1 · pre-money + amount raised, not a traded price
Total raised
$60,717
Across 1 round since 2022
Latest share price
$5.00
EXTENDED LONGEVITY, INC. Preferred Stock 1 offering price
Financials
FY2020–FY2024 · from SEC filings · hover any figure for its source$9K
−$60K
2020
$31K
−$66K
2021
$31K
−$66K
2022
$65K
−$24K
2023
$6K
$44K
2024
RevenueNet income — beside revenue when positive, below the line when a loss
Metric
FY2020
FY2021
FY2022
FY2023
FY2024
Income statement
Revenue
$8,513
$31,073
$31,073
$64,951
$6,340
Cost of goods sold
$693
$2,410
$2,410
$5,196
$0
Gross margin
92%
92%
92%
92%
100%
Net income
-$59,867
-$65,702
-$65,702
-$23,660
$44,039
Taxes paid
$0
$0
$0
$0
$0
Balance sheet
Cash
$3,245
$5,025
$5,025
$107,305
$118,266
Accounts receivable
$2,791
$7,269
$7,269
$24,477
$25,362
Total assets
$24,849
$41,128
$41,128
$168,015
$181,315
Short-term debt
$95,816
$172,497
$172,497
$170,002
$175,235
Long-term debt
$0
$5,300
$0
$4,630
$0
Total liabilities
$95,816
$177,797
$172,497
$174,632
$175,235
Other
Headcount
—
5
—
5
5
Figures as reported by the issuer in the filing shown on hover. Each year’s pill shows the assurance level of its filed statements — audited, reviewed (CPA review, less than an audit), or unaudited; no pill means the filing didn’t state one. Headcount is the filing’s point-in-time count, not a year-end average. Manually corrected figures are marked “Corrected”.
Valuation over rounds
Post-money = pre-money + amount raised · caps marked$45.1M
post-money
EXTENDED LONGEVITY, INC. Preferred Stock 1
A dashed amber step is a SAFE/note valuation cap — a conversion ceiling agreed for that instrument, not a priced valuation of the company. Steps are not comparable across bases.
Fundraising history
Raised $60.7K / $107KInvestors 55Post-money $45.1M
Reg CF annual-report compliance
Not requiredFewer than 300 holders of record
Filed 2 of 4 annual reports (FY2022–FY2025)
55 investors
holder-count proxy
Reg CF issuers must file a Form C-AR each year until a Rule 202(b) termination trigger is met.
SEC filings
Source: ManualCIK 0001901202Share price $5.00
About this data. Figures are compiled from public sources — SEC EDGAR filings (Form C, C-AR, 1-A, 1-K) and funding-platform pages — and may be delayed, incomplete, or restated by the issuer. Financial statements are as reported by the issuer; each year is labeled with its assurance level (audited / reviewed / unaudited). A valuation cap is the conversion ceiling of a SAFE or convertible note, not an agreed company valuation; post-money figures are computed as pre-money plus amount raised and are not a traded price. Crowdonomics is not a broker-dealer, funding portal, or investment adviser; nothing here is investment advice or an offer to sell securities. Verify all figures against the linked EDGAR filings.